Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Reports Positive Data from Phase II Trials of nAMD Therapy

publication date: Mar 19, 2024

Innovent Biologics (HK: 01801) reported that efdamrofusp alfa high-dose met its primary endpoint in the second Phase II trial that enrolled China patients with neovascular age-related macular degeneration (nAMD). The two Phase II studies, which compared the Innovent drug with Aflibercept, showed that IBI302 can be administered every 12 weeks. Innovent says the therapeutic properties of efdamrofusp alfa derive from its double targets: the VEGF domain that blocks angiogenesis, and the complement binding domain that inhibits an inflammatory response. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital